VERO Biotech
  • Our Story
    • Overview
    • Board of Directors
    • Leadership Team
  • Solutions
    • Overview
    • Publications
  • Updates
    • Overview
    • In the News
  • Opportunities
  • Engagement
  • CUSTOMER ORDER
  • Knowledge Center
  • Menu Menu
  • MEMBER LOGIN

In the News

You are here: Home1 / Updates2 / In the News
  • https://usme.com/

    VERO Biotech Strengthening Hospitals’ On-Demand Access to GENOSYL® DS Under Strategic Partnership with US Med-Equip

    November 6, 2023

    • https://www.prnewswire.com/news-releases/vero-biotechs-genosyl-delivery-system-recognized-as-a-technological-breakthrough-at-premier-incs-annual-supplier-innovation-celebration-301850145.html

      VERO Biotech’s GENOSYL® Delivery System recognized as a “Technological Breakthrough” at Premier, Inc.’s Annual Supplier Innovation Celebration

      June 14, 2023

      • https://www.prnewswire.com/news-releases/vero-biotechs-second-generation-genosyl-delivery-system-ds-receives-fda-approval-in-anesthesia-in-the-surgical-suite-301737882.html

        VERO Biotech’s Second Generation GENOSYL® Delivery System (DS) Receives FDA Approval in Anesthesia in the Surgical Suite

        February 2, 2023

      • https://www.prnewswire.com/news-releases/vero-biotech-raises-30-million-to-accelerate-commercialization-of-its-innovative-tankless-inhaled-nitric-oxide-delivery-system-301718655.html

        VERO Biotech Raises $30 Million to Accelerate Commercialization of Its Innovative Tankless Inhaled Nitric Oxide Delivery System

        January 11, 2023

      • https://www.prnewswire.com/news-releases/vero-biotech-receives-fda-approval-of-its-third-generation-tankless-inhaled-nitric-oxide-delivery-system-301716118.html

        VERO Biotech Receives FDA Approval of its Third Generation Tankless Inhaled Nitric Oxide Delivery System

        January 9, 2023

      • https://www.prnewswire.com/news-releases/georgia-bio-awards-vero-biotech-the-2022-golden-helix-innovation-award-and-deal-of-the-year-award-301533840.html

        Georgia Bio Awards VERO Biotech the 2022 Golden Helix Innovation Award and Deal of the Year Award

        April 27, 2022

      • https://www.prnewswire.com/news-releases/vero-biotech-receives-funding-from-mvm-partners-to-accelerate-growth-301449098.html

        VERO Biotech Receives Funding from MVM Partners to Accelerate Growth

        December 21, 2021

      • http://digitaledition.rtmagazine.com/rtmagazi/diged/20210304/index.html

        New Publication Analyzes Interhospital Transport of Newborns Using VERO Biotech’s GENOSYL® Delivery System for the Delivery of Inhaled Nitric Oxide, Pg 20-24

        April 16, 2021

      • https://www.prnewswire.com/news-releases/georgia-bio-awards-2021-golden-helix-to-vero-biotech-for-best-deal-of-the-year-301261120.html

        Georgia Bio Awards 2021 Golden Helix to VERO Biotech for Best Deal of the Year

        April 2, 2021

      • https://respiratorytherapy.ca/pdf/RT-16-2-Spring-2021-R21.pdf

        New Publication Explores Hidden Costs of Tank-Based Inhaled Nitric Oxide Delivery Systems, Pg 51-54

        March 11, 2021

      • https://gabio.org

        VERO Biotech Awarded ‘Deal of the Year’ by Georgia Biotech

        March 4, 2021

      • https://pulmonaryhypertensionnews.com

        VERO Biotech Named Top Two Stories of 2020 by Pulmonary Hypertension News

        January 5, 2021

      • www.rtmagazine.com

        Inhaled Nitric Oxide: Past, Present, and Future

        June 25, 2020

      • www.respiratorytherapy.ca

        Respiratory Therapy Newsletter June

        June 2, 2020

      • https://www.medscape.com

        Inhaled Nitric Oxide Explored for COVID-19 Oxygenation

        May 14, 2020

      • https://www.webmd.com

        Inhaled Nitric Oxide Explored for COVID-19 Oxygenation

        May 14, 2020

      • https://www.respiratorytherapy.ca

        Case Report Details Success of Tankless Delivery System

        May 13, 2020

      • www.pulmonaryhypertensionnews.com

        At-home System of Inhaled Nitric Oxide Treats PAH Patient Infected With COVID-19

        May 11, 2020

      • www.ptcommunity.com

        Home Use of GENOSYL® Delivery System (DS) to Administer GENOSYL® (nitric oxide) gas for Inhalation for the Treatment of Pulmonary Hypertension Complicated by COVID-19 Infection Published in American Journal of Respiratory and Critical Care Medicine

        May 6, 2020

      • www.galusaustralis.com

        Global Inhaled Nitric Oxide (NO) Delivery Systems Market Research Report 2020 by COVID-19 Pandemic Economic Emergency Analysis, Industry Size, Future Growth Analysis by 2027

        May 01, 2020

      • www.empr.com

        Pipeline: Immunotherapies and Other Investigational Therapies for COVID-19

        April 30, 2020

      • www.ajc.com

        Georgia manufacturing shaken by virus, but some ramp up

        April 20, 2020

      • www.itresearchbrief.com

        Trends of Inhaled Nitric Oxide (NO) Delivery Systems Market Reviewed for 2020 with Industry Outlook to 2025

        April 20, 2020

      • www.medicaldevice-network.com

        VERO Biotech uses expanded access emergency for iNO delivery system

        March 27, 2020

      • www.biocentury.com

        COVID-19 roundup: biopharmas scramble to reassess clinical timelines; plus CEPI-Dynavax, and emergency approvals for Vero, Fosun

        March 27, 2020

      • www.finance.yahoo.com

        FDA Grants VERO Biotech Expanded Access Emergency Use for the Treatment of Patients with COVID-19, with the GENOSYL® DS, the First and Only FDA-Approved Tankless System for the Delivery of Inhaled Nitric Oxide

        March 26, 2020

      • www.reuters.com

        BRIEF-FDA Grants Vero Biotech Expanded Access Emergency Use For Treatment Of Patients With COVID-19, With Genosyl Ds

        March 26, 2020

      • www.pulmonaryhypertensionnews.com

        COVID-19 Patient with PH Treated with iNO Via Genosyl, VERO Biotech Announces

        March 25, 2020

      • www.biocentury.com

        Regulatory roundup: BioMarin poised to have first U.S., EU hemophilia gene therapy; plus Allergan, Eisai, FibroGen, ViiV and Vero

        December 24, 2019

      Contact Info

      • 387 Nerem Street NW
        Suite 125
        Atlanta, Georgia 30313

      • contactus@vero-biotech.com

      • PRODUCT INQUIRIES

        To report an adverse event, product questions or complaints, other safety-related information or technical support for a company product

      • 877-337-4118

      • support@vero-biotech.com

      Quick Links

      • Our Story
      • Solutions
      • Publications
      • Opportunities
      • Prescribing Information
      • Engagement
      • Employees
      • VITA Quick Scan Mobile App

      Medical Inquiries

      For medical inquiries, click on the Request Form below.

      REQUEST FORM

      • Cigna Machine Readable Files

        This link leads to the machine-readable files that are made available in response to the federal Transparency in Coverage Rule and includes negotiated service rates and out-of- network allowed amounts between health plans and healthcare providers. The machine readable files are formatted to allow researchers, regulators, and application developers

      • Check our Privacy Policy
      • Facebook
      • LinkedIn
      • Instagram
      © Copyright - VERO Biotech. All rights reserved. VERO Biotech and GENOSYL are registered trademarks of VERO Biotech Inc.
      Indication & safety information Indication & safety info
      EXPAND

      More about Inhaled Nitric Oxide

      Nitric oxide

      A compound of one atom of nitrogen and one atom of oxygen—is a critically important molecule involved in many physiological and disease processes. This “startlingly simple” compound was dubbed Molecule of the Year in 1992 as it “unites neuroscience, physiology, and immunology, and revises scientists’ understanding of how cells communicate and defend themselves.”

      Inhaled Nitric Oxide

      Inhaled Nitric Oxide as a therapeutic agent is ideally suited to its purpose—to effect dilation of pulmonary vessels, thereby lowering pulmonary artery pressures. Importantly, delivered to the lung, and with a very short half-life of a few seconds in the blood, the effect of inhaled nitric oxide is selective for the pulmonary vasculature, rather than systemic, as with other types of vasodilators.

      GENOSYL® (nitric oxide)

      GENOSYL® (nitric oxide) gas for inhalation, relaxes vascular smooth muscle cells, which leads to vasodilation of the pulmonary capillaries. GENOSYL appears to increase the partial pressure of arterial oxygen (PaO2) by dilating pulmonary vessels in better ventilated areas of the lung, redistributing pulmonary blood flow away from lung regions with low ventilation/perfusion (V/Q) ratios toward regions with normal ratios.

      Indication & Safety Information

      GENOSYL® is indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents.

      • GENOSYL is contraindicated in the treatment of neonates dependent on right-to-left shunting of blood.
      • Abrupt discontinuation of GENOSYL (nitric oxide) gas, for inhalation may lead to worsening oxygenation and increasing pulmonary artery pressure.
      • Methemoglobin, NO2 and PaO2 should be monitored during nitric oxide administration.
      • In patients with pre-existing left ventricular dysfunction, GENOSYL may increase pulmonary capillary wedge pressure leading to pulmonary edema. The most common adverse reaction is hypotension.
      • Nitric oxide donor compounds may have an additive effect with GENOSYL on the risk of developing methemoglobinemia.
      • Only validated ventilator systems or nasal cannulas should be used in conjunction with GENOSYL.
      • See package insert for additional Important Safety Information.